Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
02:00am, Monday, 04'th Nov 2024
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
09:51am, Friday, 25'th Oct 2024
Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
10:11am, Thursday, 24'th Oct 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, B
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
02:00am, Monday, 21'st Oct 2024
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the thir
Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet
10:56am, Friday, 11'th Oct 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why
09:50am, Wednesday, 09'th Oct 2024
Verona Pharma (VRNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it throug
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
02:00am, Monday, 30'th Sep 2024
Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024.
Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
04:20am, Saturday, 14'th Sep 2024
Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER's cost-effe
Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024
02:00am, Thursday, 05'th Sep 2024
Verona Pharma presents one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre at ERS 2024.
Top 3 Health Care Stocks That May Crash In August
08:35am, Wednesday, 14'th Aug 2024
As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript
01:15pm, Thursday, 08'th Aug 2024
Verona Pharma plc (NASDAQ:VRNA ) Q2 2024 Earnings Conference Call August 8, 2024 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial O
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
02:00am, Thursday, 08'th Aug 2024
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m.
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
02:00am, Tuesday, 30'th Jul 2024
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
02:00am, Thursday, 25'th Jul 2024
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the seco
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
12:12pm, Friday, 12'th Jul 2024
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
